These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
214 related articles for article (PubMed ID: 14488260)
21. Should vaccines and antiviral therapy for influenza now be deployed strategically? Griffiths PD Rev Med Virol; 2004; 14(3):137-9. PubMed ID: 15124230 [No Abstract] [Full Text] [Related]
22. [Research progress and prospect of universal influenza vaccine]. Luo DY; Xue CY; Cao YC Bing Du Xue Bao; 2013 Nov; 29(6):646-50. PubMed ID: 24520771 [TBL] [Abstract][Full Text] [Related]
23. The evolution of seasonal influenza viruses. Petrova VN; Russell CA Nat Rev Microbiol; 2018 Jan; 16(1):47-60. PubMed ID: 29081496 [TBL] [Abstract][Full Text] [Related]
28. [Comparative studies on the detection of antibodies to influenza virus antigen using enzyme immunoassay and counterimmunoelectrophoresis]. Pohl WD; Tischner H Z Erkr Atmungsorgane; 1984; 163(2):187-90. PubMed ID: 6390994 [TBL] [Abstract][Full Text] [Related]
29. Computationally Optimized Broadly Reactive Hemagglutinin Elicits Hemagglutination Inhibition Antibodies against a Panel of H3N2 Influenza Virus Cocirculating Variants. Wong TM; Allen JD; Bebin-Blackwell AG; Carter DM; Alefantis T; DiNapoli J; Kleanthous H; Ross TM J Virol; 2017 Dec; 91(24):. PubMed ID: 28978710 [TBL] [Abstract][Full Text] [Related]
30. An interpretation of the significance of influenza virus variation for the development of an effective vaccine. SALK JE Bull N Y Acad Med; 1952 Nov; 28(11):748-65. PubMed ID: 12987937 [No Abstract] [Full Text] [Related]
31. Influenza virus-specific antibody dependent cellular cytoxicity induced by vaccination or natural infection. de Vries RD; Nieuwkoop NJ; Pronk M; de Bruin E; Leroux-Roels G; Huijskens EGW; van Binnendijk RS; Krammer F; Koopmans MPG; Rimmelzwaan GF Vaccine; 2017 Jan; 35(2):238-247. PubMed ID: 27914742 [TBL] [Abstract][Full Text] [Related]
32. Influenza-induced lung T Van Braeckel-Budimir N; Harty JT Immunol Cell Biol; 2017 Sep; 95(8):651-655. PubMed ID: 28405016 [TBL] [Abstract][Full Text] [Related]
34. Laboratory correlates of immunity to influenza - a reassessment. Proceedings of a workshop. May 2-3, 2002. Bergen, Norway. Dev Biol (Basel); 2003; 115():1-151. PubMed ID: 15612119 [No Abstract] [Full Text] [Related]
35. A comparative study of attenuated influenza viruses. Beare AS; Maassab HF; Tyrrell DA; Slepuskin AN; Hall TS Bull World Health Organ; 1971; 44(5):593-8. PubMed ID: 5316742 [TBL] [Abstract][Full Text] [Related]
36. Strategies for developing vaccines against H5N1 influenza A viruses. Horimoto T; Kawaoka Y Trends Mol Med; 2006 Nov; 12(11):506-14. PubMed ID: 17011235 [TBL] [Abstract][Full Text] [Related]
37. The effect of cupriporphyrin on antigenicity and pyrogenicity of influenza virus vaccine. FREEMAN MD; STANTON HT; BARNARD RD; GOLDMAN B Ann Allergy; 1956; 14(1):82-7. PubMed ID: 13292830 [No Abstract] [Full Text] [Related]
38. Active immunization with influenza virus A and B in infants and children. GLAZIER MM; BENENSON AS; WHEELER RE Pediatrics; 1956 Apr; 17(4):482-8. PubMed ID: 13310081 [No Abstract] [Full Text] [Related]
39. New approaches for the control of influenza. Woodland DL Viral Immunol; 2012 Feb; 25(1):1-2. PubMed ID: 22239236 [No Abstract] [Full Text] [Related]
40. Fluad--an adjuvanted seasonal influenza vaccine for older adults. Med Lett Drugs Ther; 2016 Jan; 58(1486):8. PubMed ID: 26761341 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]